Northern Light Leads $16M Series A Round In China’s Biopharma Firm Kanova

Chinese biopharmaceutical firm Kanova has secured RMB115 million (US$16.55 million) series A round of financing from Chinese venture capital firm Northern Light Venture Capital (NLVC), according to a statement released today by NLVC.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

LEAVE A REPLY